Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin in prostate cancer models

Fig. 1

a CRM1 expression in normal prostate gland and BPH (a-c) and PCa of various Gleason score (d-g) and metastases (h, i). Prostate gland and BPH1 areas expressed very low levels of XPO-1/CRM1 or were negative whereas prostate cancer areas showed different CRM1 expression both in the cytoplasm and nuclei. Metastatic lesions showed very high stains mainly in the nucleus. b, c statistical evaluation of total (Global immunoreactivity score), nuclear and cytoplasm XPO-1 expression as indicated in material and methods. d Western blot analyses and densitometric values (arbitrary/normalized densitometric values, e for XPO-1 expression in some PCa and non neoplastic epithelial cells. f Comparison between XPO-1 in AR positive (LAPC-4, CWR22, LnCaP, LnCaP-104S, LnCaP-104R1, LnCaP-C81, C4-2B, 22rv1, DuCaP, VCaP, PC3AR and DU145AR) versus AR negative (PC3 and PC3 variants [PC3PTEN, PC3M-pro4, PC3M-Ln4, PC3Me, PCb2] and DU145) PCa cells lines. g Comparison between androgen-dependent (LAPC-4, CWR22, LnCaP, LnCaP-104S, DuCaP, VCaP, PC3AR and DU145AR) versus androgen independent/CRPC (LnCaP-104R1, LnCaP-C81, C4-2B, 22rv1, PC3 and PC3 variants [PC3PTEN, PC3M-pro4, PC3M-Ln4, PC3Me, PCb2] and DU145) PCa cell lines

Back to article page
\